View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Oct. 31, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	CHF Solutions, Inc.
Entity Central Index Key	0001506492
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		625,791
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 2,513	$ 1,323
Accounts receivable	780	282
Inventory	1,337	677
Other current assets	108	137
Total current assets	4,738	2,419
Property, plant and equipment, net	575	540
Intangible assets, net	3,817	4,302
Goodwill	189	189
Other assets	21	21
TOTAL ASSETS	9,340	7,471
Current liabilities
Accounts payable and accrued expenses	1,412	2,351
Accrued compensation	815	909
Total current liabilities	2,227	3,260
Common stock warrant liability	6	1,843
Other liabilities	126	126
Total liabilities	2,359	5,229
Commitments and contingencies
Stockholders' equity
Preferred stock	0	0
Common stock as of September 30, 2017 and December 31, 2016, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 625,844 and 38,862, respectively	0	0
Additional paid-in capital	180,972	169,496
Accumulated other comprehensive income:
Foreign currency translation adjustment	1,228	1,235
Accumulated deficit	(175,219)	(168,974)
Total stockholders' equity	6,981	1,757
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	9,340	7,471
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series B-1 Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series C Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series D Convertible Preferred Stock [Member]
Temporary Stockholders' Equity
Series D convertible preferred stock as of September 30, 2017 and December 31, 2016, par value $0.0001 per share; authorized 0 and 900 shares, respectively, issued and outstanding 0 and 700, respectively	$ 0	$ 485

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	39,970,000	39,964,375.6
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	625,844	38,862
Common stock, shares outstanding (in shares)	625,844	38,862
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	30,000	30,000
Preferred stock, shares outstanding (in shares)	0	0
Series B-1 Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	0	1,824.4
Preferred stock, shares issued (in shares)	0	1,824.4
Preferred stock, shares outstanding (in shares)	0	1,824.4
Series C Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	0	2,900
Preferred stock, shares issued (in shares)	0	2,900
Preferred stock, shares outstanding (in shares)	0	2,900
Series D Convertible Preferred Stock [Member]
Temporary Stockholders' Equity
Temporary stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Temporary stock, shares authorized (in shares)	0	900
Temporary stock, shares issued (in shares)	0	700
Temporary stock, shares outstanding (in shares)	0	700
Stockholders' equity
Preferred stock, shares outstanding (in shares)	0	700

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) [Abstract]
Net sales	$ 957	$ 543	$ 2,722	$ 543
Costs and expenses:
Cost of goods sold	782	187	1,912	187
Selling, general and administrative	2,671	2,683	7,478	5,444
Research and development	367	1,735	1,002	7,511
Total costs and expenses	3,820	4,605	10,392	13,142
Loss from operations	(2,863)	(4,062)	(7,670)	(12,599)
Other income (expense):
Interest expense	0	(68)	0	(504)
Loss on early retirement of long-term debt	0	(500)	0	(500)
Other income, net	17	2	28	2
Warrant valuation expense	0	0	(67)	0
Change in fair value of warrant liability	4	646	1,470	646
Total other income (expense)	21	80	1,431	(356)
Loss before income taxes	(2,842)	(3,982)	(6,239)	(12,955)
Income tax benefit (expense), net	(5)	65	(6)	64
Net loss	$ (2,847)	$ (3,917)	$ (6,245)	$ (12,891)
Basic and diluted loss per share (in dollars per share)	$ (4.55)	$ (117.66)	$ (25.36)	$ (409.02)
Weighted average shares outstanding - basic and diluted (in shares)	626	33	359	32
Other comprehensive loss:
Foreign currency translation adjustments	$ (1)	$ (6)	$ (7)	$ (12)
Total comprehensive loss	$ (2,848)	$ (3,923)	$ (6,252)	$ (12,903)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating Activities:
Net loss	$ (6,245)	$ (12,891)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization expense	656	457
Stock-based compensation expense, net	391	764
Amortization of debt discount and financing fees	0	187
Loss on retirement of long-term debt	0	500
Change in fair value of warrant liability	(1,470)	(646)
Warrant valuation expense	67	0
Changes in operating assets and liabilities:
Accounts receivable	(498)	(111)
Inventory	(660)	(202)
Other current assets	28	256
Other assets	0	(471)
Accounts payable and accrued expenses	(1,038)	(1,406)
Net cash used in operations	(8,769)	(13,563)
Investing Activities:
Purchases of property and equipment	(206)	(110)
Acquisition of Aquadex product line	0	(4,000)
Net cash used in investing activities	(206)	(4,110)
Financing Activities:
Net proceeds from public stock offering	8,002	0
Net proceeds from exercise of warrants	1,981	0
Net proceeds from the sale of common stock, preferred stock, and warrants	184	3,362
Repayments on borrowings on long-term debt	0	(8,000)
Net cash provided by (used in) financing activities	10,167	(4,638)
Effect of exchange rate changes on cash	(2)	(10)
Net increase (decrease) in cash and cash equivalents	1,190	(22,321)
Cash and cash equivalents - beginning of period	1,323	23,113
Cash and cash equivalents - end of period	2,513	792
Supplement schedule of non-cash activities
Warrants issued as inducement to warrant exercise	509	0
Conversion of temporary equity to permanent equity	485	0
Common stock issued for business acquisition	0	950
Supplemental cash flow information
Cash paid for interest	0	840
Cash paid for income taxes	$ 8	$ 47

Nature of Business and Basis of Presentation

9 Months Ended

Sep. 30, 2017

Nature of Business and Basis of Presentation [Abstract]

Nature of Business and Basis of Presentation

Note 1 – Nature of Business and Basis of Presentation

Nature of Business: CHF Solutions, Inc. (the “Company”) is a medical device company focused on commercializing the Aquadex FlexFlow® System for Aquapheresis® therapy. The Aquadex FlexFlow System (Aquadex) is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions, Inc. is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia, Ireland and Delaware. The Company has been listed on the NASDAQ Capital Market since February 2012.

Prior to July 2016, the Company was focused on developing the C-Pulse® Heart Assist System for treatment of Class III and ambulatory Class IV heart failure. The C-Pulse System utilized the known concept of counterpulsation applied to the aorta. In March 2016, the Company announced that it was no longer enrolling patients into its two clinical studies for the C-Pulse System and that it planned to pursue a new strategic direction. In July 2016, the Company announced that it was moving forward with a therapeutic strategy utilizing neuromodulation rather than counterpulsation. In August 2016, the Company acquired the Aquadex business from a subsidiary of Baxter International, Inc. (“Baxter”), a global leader in the hospital products and dialysis markets (herein referred to as the “Aquadex Business.”) On September 29, 2016, the Company announced a strategic refocus of its near-term strategy that included halting clinical evaluations of its neuromodulation technology to fully focus its resources on its recently acquired Aquadex Business, taking actions to reduce its cash burn, and reviewing potential strategic alliances and financing alternatives. On May 23, 2017, the Company announced it was changing its name from Sunshine Heart, Inc. to CHF Solutions, Inc.to more appropriately reflect the direction of its business.

During 2017, the Company’s board of directors and stockholders approved two reverse stock splits (together, the Reverse Stock Splits). Neither reverse stock split changed the par value of the Company’s common stock or the number of common or preferred shares authorized by the Company’s Fourth Amended and Restated Certificate of Incorporation. The first reverse stock split was a 1-for-30 reverse split of the Company’s outstanding common stock that became effective after trading on January 12, 2017. The second reverse stock split was a 1-for-20 reverse split of the Company’s outstanding common stock that became effective after trading on October 12, 2017. All share and per-share amounts have been retroactively adjusted to reflect the Reverse Stock Splits for all periods presented.

Principles of Consolidation: The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive loss, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Operating results for interim periods are not necessarily indicative of results that may be expected for the year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.

For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

Going Concern: The Company’s consolidated financial statements have been prepared and presented on a basis assuming it continues as a going concern. During the years ended December 31, 2016 and 2015 and through September 30, 2017, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and comprehensive loss and cash flows, respectively. At September 30, 2017, the Company had an accumulated deficit of $175 million and it expects to incur losses for the immediate future. To date, the Company has been funded by debt and equity financings, and although the Company believes that it will be able to successfully fund its operations, there can be no assurance that it will be able to do so or that it will ever operate profitably.

The Company became a revenue generating company after acquiring the Aquadex Business in August 2016. The Company expects to incur additional losses in the near-term as it grows the Aquadex Business, including investments in expanding its sales and marketing capabilities, clinical evaluations, purchasing inventory, manufacturing components, and complying with the requirements related to being a U.S. public company. To become and remain profitable, the Company must succeed in expanding the adoption and market acceptance of the Aquadex FlexFlow. This will require the Company to succeed in training personnel at hospitals and effectively and efficiently manufacturing, marketing and distributing the Aquadex FlexFlow and related components. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability.

The Company may require additional funding in the future, which may not be available on terms favorable to the Company, or at all. The Company’s ability to continue as a going concern may be dependent on the Company’s ability to raise additional capital based on the achievement of commercial milestones. Should future capital raising be unsuccessful, the Company may not be able to continue as a going concern. On April 24, 2017, the Company closed on an underwritten public equity offering for net proceeds of approximately $8.0 million after deducting the underwriting discounts and commissions and other costs associated with the offering (see Note 4 - Equity). The Company believes it will need to raise additional funds to finance its operations in the fourth quarter of 2017 or first quarter of 2018. The Company may receive those funds from the proceeds from future warrant exercises, issuances of equity securities, or other financing transactions. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.

Revenue Recognition: The Company recognizes revenues from product sales when earned. Specifically, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue is not recognized until title and risk of loss have transferred to the customer. The shipping terms for the Company’s revenue arrangements are FOB shipping point. During the nine months ended September 30, 2017, two customers accounted for 13.9% and 10.8%, respectively, of the Company’s total net sales.

Accounts Receivable: Accounts receivable are unsecured, are recorded at net realizable value, and do not bear interest. The Company makes judgments as to its ability to collect outstanding receivables based upon significant patterns of uncollectability, historical experience, and managements’ evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers’ financial condition on an as-needed basis. Payment is generally due 30 days from the invoice date and accounts past 30 days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off against the related allowance. To date the Company has not experienced any write-offs or significant deterioration of the aging of its accounts receivable, and therefore, no allowance for doubtful accounts was considered necessary as of September 30, 2017 or December 31, 2016. At September 30, 2017, three customers accounted for 19.3%, 11.4%, and 10.4%, respectively, of the Company’s total accounts receivable. As of December 31, 2016, two customers represented 21.2%, and 17.6%, respectively, of the Company’s total accounts receivable.

Inventories: Inventories represent finished goods purchased from the Company’s supplier and are recorded as the lower of cost or market using the first-in-first out method.

Intangible assets: The Company’s intangible assets consist of customer relationships, developed technology, and trademarks and tradenames. All intangible assets recognized by the Company result from the acquisition of the Aquadex Business. All intangible assets are estimated to have a useful life of 7 years. The Company reviews its definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows derived from such assets. In cases where the carrying value exceeds the undiscounted cash flows, the carrying value is written down to its fair value, using a discounted cash flow analysis. No impairments have been identified or recorded in the periods presented.

Goodwill: Goodwill is the cost of an acquisition in excess of the fair value of acquired assets and liabilities and is recorded as an asset on the balance sheet. Goodwill is not subject to amortization but must be tested for impairment at least annually. This test requires the Company to determine if the implied fair value of the goodwill is less than its carrying amount.

The Company evaluates goodwill for impairment annually on November 1^st of each calendar year, or to the extent events or conditions indicate a risk of possible impairment during the interim periods prior to its annual impairment test. Generally, the evaluation of goodwill for impairment involves a two-step test, although under certain circumstance an initial qualitative evaluation may be sufficient to conclude that goodwill is not impaired without conducting the quantitative test.

Step 1 involves comparing the estimated fair value of each respective reporting unit to its carrying value, including goodwill. If the estimated fair value exceeds the carrying value, the reporting unit’s goodwill is not considered impaired. If the carrying value exceeds the estimated fair value, step 2 must be performed to determine whether goodwill is impaired and, if so, the amount of the impairment. Step 2 involves calculating an implied fair value of goodwill by performing a hypothetical allocation of the estimated fair value of the reporting unit determined in step 1 to the respective tangible and intangible net assets of the reporting unit. The remaining implied goodwill is then compared to the actual carrying amount of the goodwill for the reporting unit. To the extent the carrying amount of goodwill exceeds the implied goodwill, the difference is the amount of the goodwill impairment. No impairments have been identified or recorded in the periods presented.

Contingent consideration: In connection with the Company’s purchase of Aquadex, the Company has an obligation to pay additional consideration that is contingent upon the occurrence of certain future events. Contingent consideration was recognized at the acquisition date at the estimated fair value of the contingent milestone payments. The fair value of the contingent consideration is remeasured to its estimated fair value at the end of each reporting period, with changes recorded to earnings.

Common stock warrant liability: The Company recorded its common stock warrant liability at fair value at the date of issuance using primarily a Monte Carlo valuation model (see Note 6 - Fair Value of Financial Instruments). The fair value is remeasured to its estimated fair value at the end of each reporting period with changes recorded to earnings.

Earnings per share: Basic earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding. The net loss allocable to common stockholders for the nine months ended September 30, 2017, reflects a $1.0 million increase for the net deemed dividend to preferred stockholders provided in connection with the close of the public offering of Series E Convertible Preferred Stock in April of 2017 (see Note 4 - Equity), representing the intrinsic value of the shares at the time of issuance. In addition, the net loss allocable to common stockholders for the nine months ended September 30, 2017, reflects a $1.8 million increase for the net deemed dividend to preferred stockholders provided in connection with the shareholder approval of the Series C and D Convertible Preferred Stock offering in January of 2017 (see Note 4 - Equity), representing the intrinsic value of the shares at the time of issuance. Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include warrants, stock options and other stock-based awards granted under stock-based compensation plans. These potentially dilutive shares were excluded from the computation of loss per share as their effect was antidilutive due to the Company’s net loss in each of those periods.

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	September 30
	2017	2016
Stock options	36,874	4,816
Restricted stock units	324	731
Warrants to purchase common stock	496,629	6,885
Series B Convertible Preferred Stock	-	3,948
Total	533,827	16,380

New Accounting Pronouncements: In March 2016, the Financial Accounting Standards Board (FASB), issued amended stock compensation guidance to simplify various aspects of employee share-based payments accounting and presentation in the financial statements. The new guidance requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled, allows an employer to repurchase more of an employee’s shares than previously allowed for tax withholding purposes without triggering liability accounting, allows a company to make a policy election to account for forfeitures as they occur, and eliminates the requirement that excess tax benefits be realized before companies can recognize them. The new guidance also requires excess tax benefits and tax shortfalls to be presented on the cash flow statement as an operating activity rather than as a financing activity, and clarifies that cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation are to be presented as a financing activity. The standard was effective for the Company’s interim and annual periods beginning after January 1, 2017. The Company adopted the guidance in the current year. The adoption of this standard did not have a material impact to the Company’s consolidated financial statements.

In May 2014, August 2015, March 2016, April 2016 and May 2016, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The standard allows the Company to transition to the new model using either a full or modified retrospective approach. This guidance will be effective for the Company’s interim and annual periods beginning January 1, 2018. Although the assessment is not complete, the Company believes that this standard will not have a material impact on its business practices, financial condition, results of operations and disclosures. The Company expects to complete the assessment in the fourth quarter of 2017.

In November 2015, the FASB issued amended guidance concerning the classification of deferred taxes on the balance sheet to require that deferred tax assets and deferred tax liabilities be presented as noncurrent in a classified balance sheet. The amendment was effective for our annual and interim reporting periods beginning January 1, 2017, with early adoption permitted. The Company adopted this standard in the first quarter of 2017 with no impact on the Company’s consolidated financial statements as all net deferred tax assets are fully reserved.

In February 2016, the FASB issued updated guidance to improve financial reporting about leasing transactions. This guidance will require organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. This guidance is effective for the Company’s annual and quarterly reporting periods beginning January 1, 2019. The Company is evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures.

In January 2017, the FASB issued amended guidance to simplify the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test. A goodwill impairment will now be measured as the amount by which a reporting unit’s carrying value exceeds its fair value, limited to the amount of goodwill allocated to that reporting unit. This guidance is to be applied on a prospective basis effective for the Company’s interim and annual periods beginning after January 1, 2020, with early adoption permitted for any impairment tests performed after January 1, 2017. The Company is currently evaluating the effect of this update on its consolidated financial statements.

Aquadex Acquisition

9 Months Ended

Sep. 30, 2017

Aquadex Acquisition [Abstract]

Aquadex Acquisition

Note 2 – Aquadex Acquisition

On August 5, 2016, the Company completed the acquisition of certain assets used in the production and sale of the Aquadex product line from Baxter. The acquisition of these assets meets the criteria for the purchase of a business, and has been accounted for in accordance with Accounting Standards Codification (ASC) 805, Business Combinations, with identifiable assets acquired and liabilities assumed recorded at their estimated fair values on the acquisition date. A valuation of the assets and liabilities from the business acquisition was performed utilizing cost, income and market approaches resulting in $5.1 million allocated to identifiable net assets.

In connection with the acquisition of the Aquadex Business, the Company entered into a manufacturing and supply agreement with Baxter whereby Baxter agreed to manufacture and supply all of the Company’s finished goods for a period of up to 18 months from the close of the transaction. The Company completed the acquisition in order to strengthen its presence in the heart failure market.

Purchase Consideration: Total purchase consideration for the Aquadex Business was as follows:

(in thousands)
Cash consideration	$	4,000
Common stock consideration		950
Fair value of contingent consideration		126
Total purchase consideration	$	5,076

Common Stock Consideration: The common stock consideration consisted of 1,666 shares of the Company’s common stock, worth $0.95 million based on the closing market value of $570.00 per share on August 5, 2016.

Contingent Consideration: In connection with the acquisition of the Aquadex product line, the Company agreed to pay Baxter 40% of any proceeds in excess of $4.0 million related to the sale or disposal of the Aquadex assets within three years of the close of the transaction. The fair value of this contingent consideration was calculated based on the estimated likelihood of occurrence of this event in the timeframe provided by the agreement.

Purchase price consideration does not include expenses of $0.9 million for accounting, audit, legal, and valuation services that were incurred as part of the transaction and were expensed as incurred.

The acquisition was recorded by recognizing the assets acquired at their estimated fair value at the acquisition date. The excess of the cost of the acquisition over the fair value of the assets acquired was recorded as goodwill. The fair values were based on management’s analysis, including work performed by third-party valuation specialists. The following presents the amounts recognized for the assets acquired on August 5, 2016 (in thousands):

Capital lease asset	$	307
Intangible assets		4,580
Total identifiable assets acquired		4,887
Goodwill		189
Total purchase consideration	$	5,076

The goodwill is primarily attributable to new and/or future customer relationships that were not acquired in the transaction. The fair value of the capital lease asset utilized a combination of the cost and market approaches, depending on the characteristics of the asset classification. Of the $4.6 million of acquired intangible assets, $3.1 million was assigned to customer relationships, $1.1 million was assigned to developed technology, and $0.4 million was assigned to trademarks and tradename. All intangible assets are estimated to have a useful life of 7 years.

Pro Forma Condensed Combined Financial Information (Unaudited)

The following unaudited pro forma combined financial information summarizes the results of operations for three months and nine months ended September 30, 2016 as if the acquisition of Aquadex had been completed on of January 1, 2016. Pro forma information reflects adjustments that are expected to have a continuing impact on our results of operations and are directly attributable to the acquisition. The unaudited pro forma results include adjustments to reflect, among other things, direct transaction costs relating to the acquisition, the difference in intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset, and the difference in depreciation expense to be incurred based on preliminary value of the capital lease asset. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition had occurred as of January 1, 2016 or that may be obtained in the future, and do not reflect future synergies, integration costs, or other such costs or savings.

($ in thousands, except per share amounts)	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
Pro forma net sales	$	957		$	791		$	2,722		$	2,414
Pro forma net loss from operations		(2,863	)		(3,146	)		(7,670	)		(12,519	)
Pro forma basic and diluted net loss per share	$	(4.55	)	$	(94.50	)	$	(25.36	)	$	(397.21	)

Debt	9 Months Ended
Debt	Sep. 30, 2017
Debt [Abstract]
Debt	Note 3 - Debt Prior Loan Agreement: On February 18, 2015, the Company entered into a loan and security agreement with Silicon Valley Bank (the Bank) for proceeds of up to $10.0 million at an annual interest rate of 7.0%. Under this agreement, a $6.0 million term loan was funded at closing and an additional term loan in the amount of $2.0 million was funded on June 26, 2015. The proceeds from the term loans were used for general corporate and working capital purposes. Commencing on January 1, 2016, the Company began repaying the advances made in twenty-four consecutive equal monthly installments. On August 4, 2016, the Company repaid all remaining amounts outstanding under the agreement, and incurred a $0.5 million loss on early extinguishment of debt, including the accelerated write-off all unamortized warrants and debt issuance costs. There were no borrowings outstanding under this facility as of September 30, 2017 or December 31, 2016. Warrants: In connection with the funding of these term loans, the Company issued 115 warrants at an exercise price of $3,132 per share and 55 warrants at an exercise price of $2,208 per share to the Bank and one of its affiliates. The Company valued these warrants at $2,316 per share and $1,626 per share, respectively, utilizing the Black Scholes valuation model and the following assumptions: an expected dividend yield of 0%, an expected stock price volatility of 88.07% and 87.04%, a risk-free interest rate of 1.86% and 2.20%, and an expected life of 6.25 years. The warrants have a life of ten years and were fully vested at the date of grant. New Loan Agreement: On August 5, 2016, the Company entered into a new loan and security agreement with the Bank (the “New Loan Agreement”). Under the New Loan Agreement, the Bank agreed to provide the Company with up to $5.0 million in debt financing, consisting of a term loan in an aggregate original principal amount not to exceed $4.0 million (the “Term Loan”) and a revolving line of credit in an aggregate principal amount not to exceed $1.0 million outstanding at any time (the “Revolving Line”). Proceeds from the loans were to be used for general corporate and working capital purposes. Advances under the Term Loan were available to the Company until November 30, 2016 and were subject to the Company’s compliance with liquidity covenants. The Term Loan expired unused on November 30, 2016 and the Term Loan is no longer available to be drawn. Advances under the Revolving Line are available to the Company until March 31, 2020 and accrue interest at a floating annual rate equal to 1.75% or 1.0% above the prime rate, depending on liquidity factors. Advances under the revolving line are subject to various conditions precedent, including compliance with financial covenants relating to net liquidity relative to monthly cash burn, which the Company does not currently meet. Outstanding borrowings, if any, are collateralized by all of the Company’s assets, excluding intellectual property which is subject to a negative pledge. There were no borrowings outstanding under this facility as of September 30, 2017 or December 31, 2016.

Equity	9 Months Ended
Equity	Sep. 30, 2017
Equity [Abstract]
Equity	Note 4 - Equity Series B/B-1 Convertible Preferred Stock: On July 20, 2016, the Company entered into a securities purchase agreement with an institutional investor for an offering of shares of convertible preferred stock and warrants with gross proceeds of approximately $3.5 million in a registered direct offering. The transaction closed on July 26, 2016, and the Company issued 3,468 shares of Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock is non-voting and was convertible into a total of 6,149 shares of common stock at the holder’s election at any time at a conversion price of $564.0 per share. Approximately $1.6 million of the proceeds were allocated to the preferred stock, representing the residual proceeds after the warrants (described below) were recorded at fair value. On October 30, 2016, the Company entered into an exchange agreement with the holders of its Series B Convertible Preferred Stock and agreed to issue such holders 2,227.2 shares of the Company’s Series B-1 Convertible Preferred Stock in exchange for the cancellation of all shares of Series B Convertible Preferred Stock held by such holders. The Series B-1 Convertible Preferred Stock had similar terms as the Series B Convertible Preferred Stock, except that the initial conversion price of the Series B-1 Convertible Preferred Stock was $102.0 per share. As of December 31, 2016, 402.8 shares of the Series B-1 Convertible Preferred Stock had been converted into 3,948 shares of common stock, and 1,824.4 shares of Series B-1 Convertible Preferred Stock remained outstanding. As of September 30, 2017, all remaining Series B-1 Convertible Preferred Stock had been converted into an additional 17,866 shares of common stock and none remained outstanding. Series C and D Convertible Preferred Stock: Also, on October 30, 2016, the Company entered into a securities purchase agreement with an institutional investor for shares of convertible preferred stock and warrants with an aggregate purchase price of $3.8 million in a registered direct offering and simultaneous private placement. The first closing of the transaction occurred on November 3, 2016, whereby the Company received $3.6 million in gross proceeds and issued and sold 2,900 shares of Series C Convertible Preferred Stock, and 700 shares of Series D Convertible Preferred Stock, both with conversion prices of $102.0 per share. At the second closing, on January 10, 2017, the Company issued and sold 200 shares of Series D Convertible Preferred Stock with a conversion price of $102.0 per share for gross proceeds of $0.2 million. The Series C and D Convertible Preferred Stock included a contingent beneficial conversion amount of $1.3 million and $0.5 million, respectively, representing the intrinsic value of the shares at the time of issuance. This amount is reflected as an increase to the loss per share allocable to common stockholders in the first quarter of 2017 when the contingency for the conversion was resolved with the shareholder approval allowing for the conversion of the preferred stock into common stock. As of December 31, 2016, 2,900 shares of Series C Convertible Preferred Stock and 700 shares of Series D Convertible Preferred Stock were outstanding and none had been converted. As of September 30, 2017, all shares of the Series C and D Convertible Preferred Stock had been converted into an aggregate of 55,712 shares of common stock and none remained outstanding. The Series D Convertible Preferred Stock with a carrying value of $0.5 million was classified as temporary equity in the consolidated balance sheet as of December 31, 2016 because the Company could not control the settlement of its redemption in common stock. The temporary equity was not remeasured to fair value each period through earnings because the events that could trigger its redemption were not probable of occurrence. There were no shares of the Series D Convertible Preferred Stock outstanding as of September 30, 2017. Series E Convertible Preferred Stock: On April 24, 2017, the Company closed on an underwritten public offering of common stock, Series E Convertible Preferred Stock and warrants to purchase shares of common stock for gross proceeds of $9.2 million, which included the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants. Net proceeds totaled approximately $8.0 million after deducting the underwriting discounts and commissions and other costs associated with the offering. The offering comprised of Class A Units, priced at a public offering price of $20.00 per unit, with each unit consisting of one share of common stock and one five-year warrant to purchase one share of common stock with an exercise price of $22.0 per share, and Class B Units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of preferred stock, which was convertible into 50 shares of common stock, and warrants to purchase 50 shares of common stock, also with an exercise price of $22.0 per share. The conversion price of the Series E Convertible Preferred Stock as well as the exercise price of the warrants are fixed and do not contain any variable pricing features nor any price based anti-dilutive features apart from customary adjustments for splits and reverse splits of common stock. A total of 140,000 shares of common stock, 6,400 shares of Series E Convertible Preferred Stock convertible into 320,000 shares of common stock, and warrants to purchase 640,000 shares of common stock were issued in the offering including the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants. The Series E Convertible Preferred Stock included a beneficial conversion amount of $1.0 million, representing the intrinsic value of the shares at the time of issuance. This amount is reflected as an increase to the loss per share allocable to common stockholders in the nine months ended September 30, 2017. As of September 30, 2017, all shares of the Series E Convertible Preferred Stock had been converted into an aggregate of 320,000 shares of common stock and none remained outstanding. In connection with the issuance of the Series B, C and D Convertible Preferred Shares, the Company paid the placement agent an aggregate cash placement fee equal to 6% of the aggregate gross proceeds raised in the offering and issued warrants as described below. In connection with the issuance of the Series E Convertible Preferred Shares, the Company paid the placement agent an aggregate cash placement fee equal to 9% of the aggregate gross proceeds raised in the offering. There were no warrants issued to the placement agent as part of this financing. Investor Warrants: In connection with the issuance of the Series B Convertible Preferred Stock in July 2016, the Company issued the investor at no additional cost warrants to purchase 6,149 shares of common stock at an exercise price of $564.0 per share. The warrants were exercisable for 36 months commencing six months from the closing date and were subject to a reduction of the exercise price if the Company subsequently issued common stock or equivalents at an effective price less than the current exercise price of such warrants. Concurrently with the closing of the Series C and D Convertible Preferred Stock and warrant financing on November 3, 2016, the exercise price for these warrants was adjusted to $102.0 per share. In connection with the issuance of the Series C and D Convertible Preferred Stock in November 2016, the Company issued the investor at no additional cost warrants to purchase 35,295 shares of common stock at an exercise price of $108.0 per share. In connection with the issuance of the Series D Convertible Preferred Stock at the second closing in January 2017, the Company issued the investor at no additional cost warrants to purchase 1,961 shares of common stock at an exercise price of $108.0 per share. The warrants were exercisable for 60 months commencing on the earlier of the day of the receipt of approval of the Company’s stockholders of a proposal to approve the issuance of the shares of common stock underlying the warrants, or the six-month anniversary of the date of issuance. These warrants were subject to a reduction of the exercise price if the Company subsequently issued common stock or equivalents at an effective price less than the current exercise price of such warrants. Warrant Exercise Agreement: On February 15, 2017, the Company entered into a letter agreement with the institutional investors that held the majority of its outstanding warrants (the ‘‘Original Warrants’’), to incent the cash exercise of these warrants on or before March 31, 2017. In exchange for any such exercise, the Company agreed to provide the investors a replacement warrant (the ‘‘Replacement Warrants’’) to purchase the same number of shares of common stock as were issued upon exercise of the Original Warrants, with an exercise price equal to the consolidated closing bid price of its common stock on the date of issuance. The Replacement Warrants were issued in the same form as the Original Warrants except the exercise prices are not subject to reduction for subsequent equity issuances and the Replacement Warrants do not allow the investor to demand that the Company purchase the Replacement Warrants in the event of a fundamental transaction involving the Company. In connection with this agreement, between February and March 2017, the investors exercised all of the Original Warrants for gross cash proceeds to the Company of $2.0 million, and the Company issued 43,396 Replacement Warrants with exercise prices ranging from $34.6 per share to $99.8 per share. The Company entered into the letter agreement with the investors to incent the exercise of the Original Warrants in order to receive the cash proceeds from the exercise of the Original Warrants and because the exercise of the Original Warrants would allow the Company to remove the warrant liability from its balance sheet and avoid future fair value adjustments and associated volatility in its consolidated financial statements, as the Replacement Warrants are not accounted for as liabilities based on their terms. As of September 30, 2017, there were no Original Warrants outstanding and all Replacement Warrants under the letter agreement had been issued. Placement Agent Warrant: In connection with the issuance of the Series B, C and D Convertible Preferred Stock, the Company issued warrants to the placement agent to purchase an aggregate of 2,602 shares of common at exercise prices ranging from $127.6 per share to $810.0 per share. These warrants were issued at no additional cost, were exercisable immediately and expire five years from the closing of the offerings. These warrants do not contain repricing provisions. Warrant Valuation: Both the Original Warrants and placement agent warrants were accounted for as liabilities and were recorded at fair value on the date of issuance. These warrants must be measured and recorded at fair value for each subsequent reporting period that the warrants remain outstanding, and any changes in fair value must be recognized in the consolidated statement of operations and comprehensive loss. In connection with the warrant exchange agreement described above, the Company remeasured each Original Warrant as of the date of exercise and recorded $1.4 million for the change in fair value of these warrants as an unrealized gain in the accompanying consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2017. Warrant liability totaled $1.8 million as of December 31, 2016, and $6,000 as of September 30, 2017. The Replacement Warrants were valued at $0.5 million using the Black Scholes valuation model with the following assumptions: an expected dividend yield of 0%, expected stock price volatility of 49.65%-50.38%, risk-free interest rates of 1.95%-1.97% and an expected life of 5 years. The warrants have a five-year life and were fully vested at the date of grant. The terms of the Replacement Warrants do not require them to be accounted for as liabilities and are therefore recorded in equity. As in incentive to early exercise the Original Warrants, the fair value provided to investors through the Replacement Warrants exceeded the fair value of the Original Warrants that was relinquished by the warrant holders by approximately $0.1 million, which has been reflected as an expense in the consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2017.

Stock-Based Compensation

9 Months Ended

Sep. 30, 2017

Stock-Based Compensation [Abstract]

Stock-Based Compensation

Note 5 - Stock-Based Compensation

Under the fair value recognition provisions of U.S. GAAP for accounting for stock-based compensation, the Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period.

The following table presents the classification of stock-based compensation expense recognized for the periods below:

	Nine months ended September 30,
(in thousands)	2017		2016
Selling, general and administrative expense	$	351	$	506
Research and development expense		43		314
Total stock-based compensation expense	$	394	$	820

Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2017

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments

Note 6 - Fair Value of Financial Instruments

The Company’s financial instruments consist of cash equivalents, warrants, and contingent consideration.

Pursuant to the requirements of ASC Topic 820 “Fair Value Measurement,” the Company’s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:

·	Level 1 - Financial instruments with unadjusted quoted prices listed on active market exchanges.

Level 2 - Financial instruments lacking unadjusted, quoted prices from active market exchanges, including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

·	Level 3 - Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.

The fair value of the Company’s common stock warrant liability related to the Original Warrants was calculated using a Monte Carlo valuation model and was classified as Level 3 in the fair value hierarchy. The common stock warrants issued July 26, 2016 had a fair value of $226,000 on December 31, 2016 and $46,000 as of their dates of exercise. The common stock warrants issued November 3, 2016 had a fair value of $1.5 million on December 31, 2016 and $0.4 million as of their exercise dates. The common stock warrants issued January 12, 2017 had a fair value $72,000 on the date of issuance and $18,000 as of the date of exercise. All Original Warrants were classified as a warrant liability and were exercised during the nine months ended September 30, 2017.

The fair value of the Company’s common stock warrant liability related to the placement agent warrants is calculated using a Black Scholes valuation model and is classified as Level 3 in the fair value hierarchy.

Fair values were calculated using the following assumptions:

		As of Dec. 31, 2016			As of date of exercise
Risk-free interest rates, adjusted for continuous compounding		1.47/1.96	%		1.45-1.99	%
Term (years)		3.1/5.3			2.84-5.50
Expected volatility		55.3/49.8	%		49.9-58.5	%
Dates and probability of future equity raises	various			various

The fair value of the Company's contingent consideration, as described in Note 2, was initially measured based on the consideration expected to be transferred (probability-weighted), discounted back to present value, and it is considered a Level 3 instrument. The discount rate used was determined at the time of measurement in accordance with accepted valuation methods. The Company measures the liability on a recurring basis using Level 3 inputs including probabilities of payment and projected payment dates. Changes to any of the inputs may result in significantly higher or lower fair value measurements. There were no changes in the fair value of the contingent consideration subsequent to the initial measurement.

All cash equivalents are considered Level 1 measurements for all periods presented. The Company does not have any financial instruments classified as Level 2 or any other classified as Level 3 and there were no movements between these categories during the periods ended September 30, 2017 and December 31, 2016. The Company believes that the carrying amounts of all remaining financial instruments approximate their fair value due to their relatively short maturities.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2017
Income Taxes [Abstract]
Income Taxes	Note 7 – Income Taxes The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the net deferred tax assets. The Company has established a full valuation allowance for U.S. and foreign deferred tax assets due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, the Company has not reflected any benefit of such net deferred tax assets in the accompanying consolidated financial statements. During 2017, the Company experienced an ownership change as defined in Section 382 of the Internal Revenue Code which will limit the ability to utilize the Company’s net operating losses (NOLs). The Company may have experienced additional ownership changes in earlier years further limiting the NOL carry-forwards that may be utilized. The Company has not yet completed a formal Section 382 analysis. The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change. As of September 30, 2017, there were no material changes to what the Company disclosed regarding tax uncertainties or penalties in its Annual Report on Form 10-K for the year ended December 31, 2016.

Nature of Business and Basis of Presentation (Policies)

9 Months Ended

Sep. 30, 2017

Nature of Business and Basis of Presentation [Abstract]

Principles of Consolidation

For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

Inventories: Inventories represent finished goods purchased from the Company’s supplier and are recorded as the lower of cost or market using the first-in-first out method.

Intangible Assets

Goodwill

Contingent Consideration

Common Stock Warrant Liability

Earnings Per Share

	September 30
	2017	2016
Stock options	36,874	4,816
Restricted stock units	324	731
Warrants to purchase common stock	496,629	6,885
Series B Convertible Preferred Stock	-	3,948
Total	533,827	16,380

New Accounting Pronouncements

Nature of Business and Basis of Presentation (Tables)

9 Months Ended

Sep. 30, 2017

Nature of Business and Basis of Presentation [Abstract]

Potential Shares of Common Stock not Included in Diluted Net Loss Per Share

	September 30
	2017	2016
Stock options	36,874	4,816
Restricted stock units	324	731
Warrants to purchase common stock	496,629	6,885
Series B Convertible Preferred Stock	-	3,948
Total	533,827	16,380

Aquadex Acquisition (Tables)

9 Months Ended

Sep. 30, 2017

Aquadex Acquisition [Abstract]

Purchase Consideration for Business

Purchase Consideration: Total purchase consideration for the Aquadex Business was as follows:

(in thousands)
Cash consideration	$	4,000
Common stock consideration		950
Fair value of contingent consideration		126
Total purchase consideration	$	5,076

Amounts Recognized for Assets Acquired

The following presents the amounts recognized for the assets acquired on August 5, 2016 (in thousands):

Capital lease asset	$	307
Intangible assets		4,580
Total identifiable assets acquired		4,887
Goodwill		189
Total purchase consideration	$	5,076

Summary of Pro Forma Information

($ in thousands, except per share amounts)	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
Pro forma net sales	$	957		$	791		$	2,722		$	2,414
Pro forma net loss from operations		(2,863	)		(3,146	)		(7,670	)		(12,519	)
Pro forma basic and diluted net loss per share	$	(4.55	)	$	(94.50	)	$	(25.36	)	$	(397.21	)

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Stock-Based Compensation [Abstract]

Summary of Classification of Stock-based Compensation Expense

The following table presents the classification of stock-based compensation expense recognized for the periods below:

	Nine months ended September 30,
(in thousands)	2017		2016
Selling, general and administrative expense	$	351	$	506
Research and development expense		43		314
Total stock-based compensation expense	$	394	$	820

Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2017

Fair Value of Financial Instruments [Abstract]

Schedule of Fair Value Assumptions

Fair values were calculated using the following assumptions:

		As of Dec. 31, 2016			As of date of exercise
Risk-free interest rates, adjusted for continuous compounding		1.47/1.96	%		1.45-1.99	%
Term (years)		3.1/5.3			2.84-5.50
Expected volatility		55.3/49.8	%		49.9-58.5	%
Dates and probability of future equity raises	various			various

Nature of Business and Basis of Presentation (Details) $ in Thousands				1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Oct. 12, 2017	Apr. 24, 2017 USD ($)	Jan. 12, 2017	Mar. 31, 2016 Study	Sep. 30, 2017 USD ($)	Sep. 30, 2017 USD ($) StockSplit Customer shares	Sep. 30, 2016 USD ($) shares	Dec. 31, 2016 USD ($) Customer
Nature of Business [Abstract]
Number of clinical studies for C-Pulse System \| Study				2
Number of reverse stock split \| StockSplit						2
Reverse stock split ratio	20		30
Going Concern [Abstract]
Retained earnings (accumulated deficit)					$ (175,219)	$ (175,219)		$ (168,974)
Net proceeds from issuance of convertible preferred stock		$ 8,000
Accounts Receivable [Abstract]
Accounts receivables maximum credit period from invoice date						30 days
Allowance for doubtful accounts					0	$ 0		$ 0
Intangible Assets [Abstract]
Estimated useful life						7 years
Intangible assets impairments loss						$ 0	$ 0
Goodwill [Abstract]
Goodwill impairment loss						$ 0	$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares) \| shares						533,827	16,380
Net Sales [Member]
Revenue Recognition [Abstract]
Number of customers \| Customer						2
Accounts Receivable [Member]
Revenue Recognition [Abstract]
Number of customers \| Customer						3		2
Series C and D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net deemed dividend to preferred shareholders						$ 1,800
Series E Convertible Preferred Stock [Member]
Going Concern [Abstract]
Net proceeds from issuance of convertible preferred stock		$ 8,000
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net deemed dividend to preferred shareholders					$ 1,000	$ 1,000
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares) \| shares						0	3,948
Customer One [Member] \| Net Sales [Member]
Revenue Recognition [Abstract]
Concentration of risk						13.90%
Customer One [Member] \| Accounts Receivable [Member]
Revenue Recognition [Abstract]
Concentration of risk						19.30%		21.20%
Customer Two [Member] \| Net Sales [Member]
Revenue Recognition [Abstract]
Concentration of risk						10.80%
Customer Two [Member] \| Accounts Receivable [Member]
Revenue Recognition [Abstract]
Concentration of risk						11.40%		17.60%
Customer Three [Member] \| Accounts Receivable [Member]
Revenue Recognition [Abstract]
Concentration of risk						10.40%
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares) \| shares						36,874	4,816
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares) \| shares						324	731
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares) \| shares						496,629	6,885

Aquadex Acquisition (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
	Aug. 05, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Amounts recognized for assets acquired [Abstract]
Goodwill		$ 189		$ 189		$ 189
Aquadex Product Line [Member]
Total purchase consideration [Abstract]
Cash consideration	$ 4,000
Common stock consideration	950
Fair value of contingent consideration	126
Total purchase consideration	$ 5,076
Common stock issued in acquisition (in shares)	1,666
Closing market value (in dollars per share)	$ 570.00
Contingent consideration payable in excess of sale or disposal of business assets	40.00%
Sale or disposal of business assets threshold for contingent consideration	$ 4,000
Acquisition related expenses	900
Amounts recognized for assets acquired [Abstract]
Capital lease asset	307
Intangible assets	4,580
Total identifiable assets acquired	4,887
Goodwill	189
Total purchase consideration	5,076
Estimated useful life				7 years
Pro forma information [Abstract]
Pro forma net sales		957	$ 791	$ 2,722	$ 2,414
Pro forma net loss from operations		$ (2,863)	$ (3,146)	$ (7,670)	$ (12,519)
Pro forma basic and diluted net loss per share (in dollars per share)		$ (4.55)	$ (94.50)	$ (25.36)	$ (397.21)
Aquadex Product Line [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Agreement term				18 months
Total purchase consideration [Abstract]
Contingent consideration period				3 years
Aquadex Product Line [Member] \| Trademarks and Tradename [Member]
Amounts recognized for assets acquired [Abstract]
Intangible assets	400
Aquadex Product Line [Member] \| Customer Relationships [Member]
Amounts recognized for assets acquired [Abstract]
Intangible assets	3,100
Aquadex Product Line [Member] \| Developed Technology [Member]
Amounts recognized for assets acquired [Abstract]
Intangible assets	$ 1,100

Debt, Prior Loan Agreement (Details) $ in Thousands					3 Months Ended		9 Months Ended
Debt, Prior Loan Agreement (Details) $ in Thousands	Aug. 04, 2016 USD ($)	Jan. 01, 2016 Installment	Jun. 26, 2015 USD ($)	Feb. 18, 2015 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 5,000		$ 5,000
Loss on early retirement of long-term debt	$ (500)				0	$ (500)	0	$ (500)
Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 10,000
Annual interest rate				7.00%
Proceeds from term loan used for general corporate and working capital			$ 2,000	$ 6,000
Consecutive equal monthly installments \| Installment		24
Total borrowings outstanding					$ 0		$ 0		$ 0

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

Debt, Warrants (Details)	9 Months Ended
Debt, Warrants (Details)	Sep. 30, 2017 $ / shares shares
Affiliates [Member]
Debt Instrument [Line Items]
Warrants issued (in shares) \| shares	55
Exercise price of warrants (in dollars per share)	$ 2,208
Value of warrants (in dollars per share)	$ 1,626
Expected dividend yield	0.00%
Expected stock price volatility	87.04%
Risk-free interest rate	2.20%
Expected warrant option life	6 years 3 months
Term of warrants	10 years
Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Warrants issued (in shares) \| shares	115
Exercise price of warrants (in dollars per share)	$ 3,132
Value of warrants (in dollars per share)	$ 2,316
Expected dividend yield	0.00%
Expected stock price volatility	88.07%
Risk-free interest rate	1.86%
Expected warrant option life	6 years 3 months
Term of warrants	10 years

Debt, New Loan Agreement (Details) - USD ($) $ in Millions	9 Months Ended
Debt, New Loan Agreement (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 5.0
Term Loan [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	4.0
Revolving Line [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1.0
Maturity date	Mar. 31, 2020
Total borrowings outstanding	$ 0.0	$ 0.0
Revolving Line [Member] \| Floating Annual Rate [Member]
Debt Instrument [Line Items]
Interest rate	1.75%
Revolving Line [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Interest rate	1.00%

- Definition

+ References + Details

Equity, Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands							9 Months Ended		12 Months Ended
	Apr. 24, 2017	Jan. 10, 2017	Nov. 03, 2016	Oct. 30, 2016	Jul. 26, 2016	Jul. 20, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock and Warrants						$ 3,500	$ 184	$ 3,362
Preferred stock, shares outstanding (in shares)							0		0
Net proceeds from issuance of convertible preferred stock	$ 8,000
Common stock, shares issued (in shares)							625,844		38,862
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock issued (in shares)					3,468
Number of preferred shares converted to common stock (in shares)					6,149
Conversion price (in dollars per share)					$ 564.0
Proceed from issuance of preferred stock					$ 1,600
Series B-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock issued (in shares)				2,227.2			0		1,824.4
Number of preferred shares converted to common stock (in shares)							17,866		3,948
Conversion price (in dollars per share)				$ 102.0
Number of convertible preferred shares converted (in shares)									402.8
Preferred stock, shares outstanding (in shares)							0		1,824.4
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock issued (in shares)			2,900				0		2,900
Number of preferred shares converted to common stock (in shares)									0
Conversion price (in dollars per share)			$ 102.0
Preferred stock, shares outstanding (in shares)							0		2,900
Beneficial conversion amount		$ 1,300
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock and Warrants		$ 200
Preferred stock issued (in shares)		200	700
Number of preferred shares converted to common stock (in shares)									0
Conversion price (in dollars per share)		$ 102.0	$ 102.0
Preferred stock, shares outstanding (in shares)							0		700
Beneficial conversion amount		$ 500
Temporary equity							$ 0		$ 485
Series C and D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock and Warrants			$ 3,600	$ 3,800
Number of preferred shares converted to common stock (in shares)							55,712
Preferred stock, shares outstanding (in shares)							0
Series B, C And D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Percentage of placement fee offered in cash							6.00%
Class A Units [Member]
Class of Stock [Line Items]
Public offering price (in dollars per share)							$ 20.00
Number of common stock (in shares)							1
Class A Units [Member] \| Warrants [Member]
Class of Stock [Line Items]
Number of preferred shares converted to common stock (in shares)							1
Term of warrants							5 years
Number of warrants (in shares)							1
Exercise price of warrants (in dollars per share)							$ 22.00
Class B Units [Member]
Class of Stock [Line Items]
Number of preferred shares converted to common stock (in shares)							50
Public offering price (in dollars per share)							$ 1,000
Number of preferred stock per unit (in shares)							1
Class B Units [Member] \| Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase shares of common stock (in shares)							50
Exercise price of warrants (in dollars per share)							$ 22.00
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock issued (in shares)							6,400
Number of preferred shares converted to common stock (in shares)							320,000
Proceed from issuance of preferred stock	9,200
Preferred stock, shares outstanding (in shares)							0
Beneficial conversion amount							$ 1,000
Percentage of placement fee offered in cash							9.00%
Net proceeds from issuance of convertible preferred stock	$ 8,000
Common stock, shares issued (in shares)							140,000
Series E Convertible Preferred Stock [Member] \| Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase shares of common stock (in shares)							640,000
Warrants issued to the placement agent (in shares)							0

Equity, Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands					2 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Feb. 15, 2017	Jan. 10, 2017	Nov. 03, 2016	Jul. 26, 2016	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Class of Stock [Line Items]
Proceeds from exercise of warrants								$ 1,981	$ 0
Warrants outstanding						$ 6		6		$ 1,843
Change in fair value of warrant liability						4	$ 646	1,470	$ 646
Minimum [Member]
Class of Stock [Line Items]
Expected stock price volatility	49.90%									49.80%
Risk-free interest rate	1.45%									1.47%
Expected warrant option life	2 years 10 months 2 days									3 years 1 month 6 days
Maximum [Member]
Class of Stock [Line Items]
Expected stock price volatility	58.50%									55.30%
Risk-free interest rate	1.99%									1.96%
Expected warrant option life	5 years 6 months									5 years 3 months 18 days
Replacement Warrants [Member]
Class of Stock [Line Items]
Warrants outstanding						$ 500		$ 500
Expected dividend yield								0.00%
Expected warrant option life								5 years
Replacement Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Expected stock price volatility								49.65%
Risk-free interest rate								1.95%
Replacement Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Expected stock price volatility								50.38%
Risk-free interest rate								1.97%
Series B Convertible Preferred Stock [Member] \| Investor Warrants [Member]
Class of Stock [Line Items]
Warrants issuance cost				$ 0
Warrants to purchase shares of common stock (in shares)				6,149
Exercise price of warrants (in dollars per share)				$ 564.0
Warrants exercisable period				36 months
Period warrants became exercisable from closing date				6 months
Series D Convertible Preferred Stock [Member] \| Investor Warrants [Member]
Class of Stock [Line Items]
Warrants issuance cost		$ 0
Warrants to purchase shares of common stock (in shares)		1,961
Exercise price of warrants (in dollars per share)		$ 108.0
Warrants exercisable period		60 months
Period warrants became exercisable from closing date		6 months
Series C and D Convertible Preferred Stock [Member] \| Investor Warrants [Member]
Class of Stock [Line Items]
Warrants issuance cost			$ 0
Warrants to purchase shares of common stock (in shares)			35,295
Exercise price of warrants (in dollars per share)			$ 108.0
Adjusted exercise price of warrants (in dollars per share)			$ 102.0
Series B, C And D Convertible Preferred Stock [Member] \| Placement Agent Warrant [Member]
Class of Stock [Line Items]
Warrants issuance cost								$ 0
Warrants to purchase shares of common stock (in shares)						2,602		2,602
Expiration term of warrants								5 years
Series B, C And D Convertible Preferred Stock [Member] \| Placement Agent Warrant [Member] \| Minimum [Member]
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share)						$ 127.6		$ 127.6
Series B, C And D Convertible Preferred Stock [Member] \| Placement Agent Warrant [Member] \| Maximum [Member]
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share)						$ 810.0		$ 810.0
Warrant Exercise Agreement [Member] \| Original Warrants [Member]
Class of Stock [Line Items]
Proceeds from exercise of warrants					$ 2,000
Warrants outstanding						$ 0		$ 0
Relinquished amount of warrants								$ 100
Warrant Exercise Agreement [Member] \| Replacement Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase shares of common stock (in shares)					43,396
Warrant Exercise Agreement [Member] \| Replacement Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share)					$ 34.6
Warrant Exercise Agreement [Member] \| Replacement Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share)					$ 99.8

Stock-Based Compensation (Details) - USD ($) $ in Thousands	9 Months Ended
Stock-Based Compensation (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 394	$ 820
Selling, General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	351	506
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 43	$ 314

Fair Value of Financial Instruments (Details) - USD ($)			9 Months Ended		12 Months Ended
Fair Value of Financial Instruments (Details) - USD ($)	Feb. 15, 2017	Jan. 12, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Common stock warrants fair value			$ 509,000	$ 0
Fair Value Transfers Between Levels [Abstract]
Level 1 to level 2 asset transfers			0		$ 0
Level 2 to level 1 asset transfers			0		0
Level 1 to level 2 liability transfers			0		0
Level 2 to level 1 liability transfers			$ 0		$ 0
Minimum [Member]
Fair Value Assumptions [Abstract]
Risk-free interest rates, adjusted for continuous compounding	1.45%				1.47%
Term	2 years 10 months 2 days				3 years 1 month 6 days
Expected volatility	49.90%				49.80%
Maximum [Member]
Fair Value Assumptions [Abstract]
Risk-free interest rates, adjusted for continuous compounding	1.99%				1.96%
Term	5 years 6 months				5 years 3 months 18 days
Expected volatility	58.50%				55.30%
Level 3 [Member] \| Warrants Issued July 26 2016 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Common stock warrants fair value	$ 46,000				$ 226,000
Level 3 [Member] \| Warrants Issued November 3 2016 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Common stock warrants fair value	400,000				$ 1,500,000
Level 3 [Member] \| Warrants Issued January 12 2017 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Common stock warrants fair value	$ 18,000	$ 72,000